Also trades as: NUVB (NYSE) · $vol 36M
NUVB-WT NYSE
Nuvation Bio Inc.
1W: +17.4%
1M: +9.6%
3M: +16.4%
YTD: -75.4%
1Y: -57.6%
$0.07
-0.00 (-0.86%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$23.0M
52W Range0.0051-0.1444
Volume81,813
Avg Volume52,014
Beta2.05
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEODavid Hung
Employees72
SectorHealthcare
IndustryBiotechnology
IPO Date2021-02-11
Websitenuvationbio.com
1500 Broadway, Suite 1401
New York, NY 10036
US
New York, NY 10036
US
+1 646 616 2000
About Nuvation Bio Inc.
Nuvation Bio Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for oncology. The company's pipeline includes small molecule drug candidates aimed at treating various types of cancer. Its strategy involves acquiring and developing novel therapeutic candidates to address significant unmet medical needs in cancer treatment.
Latest News
Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering
Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes
Nuvation Bio Inc. Q1 2026 Earnings Call Summary
Brokerages Set Nuvation Bio Inc. (NYSE:NUVB) Target Price at $11.63
Kerry Wentworth Sells 200,000 Shares of Nuvation Bio (NYSE:NUVB) Stock
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Wentworth Kerry | M-Exempt | 36,750 | $2.93 | 2026-04-17 |
| Wentworth Kerry | M-Exempt | 36,750 | $2.93 | 2026-04-17 |
| Wentworth Kerry | S-Sale | 36,750 | $5.01 | 2026-04-17 |
| Liu Dongfang | M-Exempt | 50,000 | $1.94 | 2026-04-17 |
| Liu Dongfang | M-Exempt | 50,000 | $1.94 | 2026-04-17 |